Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Appili Therapeutics has announced that its shareholders have overwhelmingly approved a plan of arrangement for Aditxt Inc. to acquire all of its Class A common shares. This transaction marks a significant milestone for Appili as it aims to enhance its pipeline of anti-infective therapies and expand its reach in the medical countermeasure field.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.